Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.
Welcoming Comments
Michael F. Bigham, Chief Executive Officer and Chairman of the Board

Unmet Need & Why NUZYRA™ Matters
Evan Loh, M.D., President, Chief Operating Officer & Chief Medical Officer

NUZYRA Commercial Strategy: 2019 and Beyond
Adam Woodrow, Chief Commercial Officer

Panel Q&A with:
- Michael F. Bigham, CEO and Chairman of the Board
- Evan Loh, M.D., President, COO & CMO
- Adam Woodrow, CCO
- Douglas W. Pagán, CFO
Welcoming Comments

Michael F. Bigham,
Chief Executive Officer & Chairman of the Board

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.
Safe Harbor Statement

Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The information contained in this presentation is accurate only as of the date hereof. “Paratek” and the Paratek logo are trademarks and service marks of Paratek. All other trademarks, service marks, trade names, logos and brand names identified in this presentation are the property of their respective owners.

Certain statements in this presentation, including responses to questions, contain or may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include, but are not limited to, statements about our strategy, future operations, prospects, plans, objectives of management, availability of data from our clinical studies, potential use of our product candidates, including Omadacycline and Sarecycline, the market acceptance of our product candidates, the strength of, and protection offered by, our intellectual property position, the potential clinical risks and efficacy of, and market opportunities for, our product candidates, the timing and stability of our supply chain, the timing of clinical development of, and regulatory approval for, our product candidates, and the nature and timing of our collaboration agreements with respect to our product candidates. The words “anticipate,” “estimate,” “expect,” “potential,” “will,” “project” and similar terms and phrases are used to identify forward-looking statements. These statements are based on current information and belief and are not guarantees of future performance. Our ability to predict results, financial or otherwise, or the actual effect of future plans or strategies, is inherently uncertain and actual results may differ from those predicted depending on a variety of factors. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations or whether the forward-looking statements ultimately prove to be correct. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include: delays in clinical trials or unexpected results; the risk that data to date and trends may not be predictive of future results; the failure of collaborators to perform obligations under our collaboration agreements; our failure to obtain regulatory approval for our product candidates; if we obtain regulatory approval for our product candidates, the risk that the terms of such approval may limit how we manufacture and market our product candidates; delays in our supply chain, delays in undertaking or completing clinical trials; our products not gaining the anticipated acceptance in the marketplace or acceptance being delayed; our products not receiving reimbursement from healthcare payors; the effects of competition; our inability to protect our intellectual property and proprietary technology through patents and other means; the need for substantial additional funding to complete the development and commercialization of our product candidates; and the other risks described in the “Risk Factors” section and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2017, and our other filings with the SEC.

PARATEK® and the Hexagon Logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA and its design logo are trademarks of Paratek Pharmaceuticals, Inc.
# Paratek Pipeline

## Compelling Life-cycle Opportunities

<table>
<thead>
<tr>
<th>Research</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Pre-Registration</th>
<th>NDA Filing</th>
<th>NDA Approved</th>
<th>Commercial Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSSSI (IV &amp; Oral) – QIDP + SPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Global*)</td>
</tr>
<tr>
<td>ABSSSI (Oral only) – QIDP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PARATEK®</td>
</tr>
<tr>
<td>CABP (IV &amp; Oral) – QIDP + SPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>uUTI (IV &amp; Oral) – QIDP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyelonephritis (IV &amp; Oral) – QIDP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biodefense Pathogens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FDA Animal Rule</td>
</tr>
</tbody>
</table>

**SEYSARA™**

(sarecycline)

- **Inflammatory Acne (Acne Vulgaris)**

*We have entered into a collaboration agreement with Zai Lab (Shanghai) Co., Ltd., for greater China region*
### Omadacycline Events

<table>
<thead>
<tr>
<th>Timing</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2 2016</td>
<td>Positive Phase 3 data</td>
</tr>
<tr>
<td>Q4 2016</td>
<td>Proof-of-principle</td>
</tr>
<tr>
<td>Q2 2017</td>
<td>Positive Phase 3 data</td>
</tr>
<tr>
<td>Q3 2017</td>
<td>Positive Phase 3 data</td>
</tr>
<tr>
<td>Q4 2017</td>
<td>Enrolling</td>
</tr>
<tr>
<td>Oct 2018</td>
<td>Approved</td>
</tr>
</tbody>
</table>

- **ABSSSI Phase 3 data: IV and oral**
- **UTI Phase 1b data: PK/PD**
- **CABP Phase 3 data: IV and oral**
- **ABSSSI Phase 3 data: Oral-only**
- **UTI Phase 2 initiation**
- **NDA approval**
- **Projected U.S. Launch**
- **Projected EMA Approval**

### Sarecycline Events

<table>
<thead>
<tr>
<th>Timing</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 2017</td>
<td>Positive Phase 3 data</td>
</tr>
<tr>
<td>Oct 2018</td>
<td>Approved</td>
</tr>
<tr>
<td>Jan 2019</td>
<td></td>
</tr>
</tbody>
</table>

- **Phase 3 efficacy studies**
- **NDA Approval**
- **Projected U.S. Launch**

---

1. Almirall, S.A. licensed U.S. development & commercial rights
Well-Positioned for Future Growth
Focused on Execution + New Value Creation

Near-term Focus

- Launch of NUZYRA
- Prudent Operating Expense Management
- Non-Dilutive Sources of Capital

New Sources of Value

- Life-cycle Opportunities for NUZYRA
- Bio-Defense
- Product / Pipeline Expansion
Strong Balance Sheet

<table>
<thead>
<tr>
<th>Key Metrics (unaudited)</th>
<th>6/30/18 balance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cash, Cash Equivalents, and Marketable Securities</td>
<td>$321.1 million</td>
</tr>
<tr>
<td>Gross Long-term Debt Obligation</td>
<td>$218.5 million</td>
</tr>
<tr>
<td>Basic Shares Outstanding</td>
<td>31,443,149</td>
</tr>
<tr>
<td>Stock Options, Restricted Stock Units, and Warrants Outstanding</td>
<td>5,760,108</td>
</tr>
</tbody>
</table>

Funding Projected through Q1 2021
Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.
The Growing Antimicrobial Resistance (AMR) Crisis
*Is Here Today, Life-Threatening and Costly*

If nothing is done, we risk falling into an era without effective antimicrobials.

Drug resistant infections cost the US $20 billion in excess healthcare costs & $35 billion in lost productivity annually.

More Deaths from AMR than Cancer in 2050.
Community-acquired bacterial pneumonia (CABP) in adults

Acute bacterial skin and skin structure infections (ABSSSI) in adults

First Once-daily IV and Oral Antibiotic to be FDA Approved to Treat Both CABP and ABSSSI in Nearly 20 Years
Significant Unmet Need in CABP

Important Demography:
- Together with influenza, CABP is currently the eighth leading cause of death in the U.S.\textsuperscript{3}
  - All cause 30-day mortality in hospitalized patients exceeds 10\%\textsuperscript{4-6}
- Hospitalization Rates in CABP are increased in older populations and in populations with certain co-morbid conditions, including COPD, CHF, and diabetes\textsuperscript{7}

\begin{itemize}
  \item S. pneumoniae
  \item S. aureus
  \item Legionella pneumophila
  \item H. influenzae
  \item Other
\end{itemize}

\textbf{CABP Pathogens}\textsuperscript{2}

\begin{itemize}
  \item 35\%
  \item 22\%
  \item 13\%
  \item 11\%
  \item 10\%
  \item 9\%
  \item >1
\end{itemize}

References:
NUZYRA Opportunities Beyond Current CABP Treatment Options: Addressing Limited Formulations with Safety Concerns

**Inpatient Rx Non-ICU**

Beta-lactam + Macrolide  \( \text{OR} \)  Respiratory Fluoroquinolone

**NUZYRA as First-Line Therapy:**
Monotherapy, IV + Oral, when \( \beta \)-lactam/Macrolide or Quinolones are not options

---

Scarcity of Effective & Safe Broad Spectrum IV + Oral Antibiotics

NUZYRA: First Once-daily CABP Indication Approved in Nearly 20 Years

1990’s

- ZITHROMAX IV/Oral
- LEVAQUIN IV/Oral
- AVELOX IV/Oral

2000

- ZIGAN Oral
- TROVAN IV/Oral
- TEQUIN IV/Oral
- KETEK Oral

2010

2016

2018

- SOLITHERA IV/Oral

Withdrawn from the market due to Toxicity

- Generic

CRL from FDA; Liver toxicity
Significant Unmet Need in Skin Infections

Important Demography:

- Incidence of skin infections requiring hospitalization has substantially increased since the 2000’s¹,³
- ~ 870,000 admissions, 6.3M office visits, and 3.4M emergency department visits annually⁵
- Underlying co-morbidities including diabetes and vascular disease can complicate management and antibiotic selection⁴

Common Skin Pathogens²

- MRSA
- MSSA
- Beta-hemolytic Streptococci
- Other Gram positive
- Anaerobe
- Other Streptococci
- Gram negative

NUZYRA as First-Line Therapy:
Monotherapy, IV + Oral, when Vancomycin/Zyvox +/- Pip/Tazo are not options

NUZYRA: A Modernized Tetracycline
Restoring Tetracycline Efficacy with Convenience Attributes

7-Position Modification:
Overcomes Efflux Pump

- $T_{1/2} = 16$ Hours
- Clinical and in-vitro activity against select: Gram-positives, Gram-negatives, Atypicals, Drug-resistant strains
- Not metabolized
- No P450 Interactions
- Biliary and renal excretion

9-Position Modification:
Overcomes Ribosomal Protection
NUZYRA: A Modernized Tetracycline
Clinically Meaningful Attributes Drive Trial to Adoption

- Once-daily IV & Oral
- High & durable clinical efficacy
- No dosage modifications or monitoring in hepatic or renal impairment
- No QTc prolongation
- Low potential for DDIs
- No cases of *C. diff* reported in completed clinical program

N U Z Y R A™
(omadacycline)

- **HCP confidence in treating patients**
  - Efficacy
  - Safety
  - Tolerability

- **Efficacy from hospital to home**
  - Helps minimize hospitalization
Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.
NUZYRA: U.S. Timeline
Investor Day 2018

- Commercial Team Hired
- Payer Mktg Team Hired
- Advisory Boards
- Market Research
- Disease State Education
- Initial Payer Research
- Campaign Development

- Account Teams Hired
- MSDs Hired/Deployed

- NDA Submitted
- NDA Planned

- KPI Dashboard
- Sales Management & ISR Hired
- Sales Teams Hired and Trained
- Trademark Review Complete
- Product Supply
- Payer Reimbursement and Trade Discussions
- Finalize Pricing

- Budget Impact Model and Health Economic Analysis and Publications
- Scientific Exchange
- Publications/News Flow Continues
NUZYRA: U.S. Timeline
Launch February 2019

Regulatory

- NDA Submitted
- NDA Accepted
- Ad Comm Completed
- Trademark Review
  - Complete
- Product Supply
- Finalize Pricing
- Scientific Exchange
- Publications/News Flow Continues

Commercial Readiness:
- Commercial Team Hired
- Payer Mktg Team Hired
- Advisory Boards
- Market Research
- Disease State Education
- Initial Payer Research
- Campaign Development

MSDs Hired/Deployed

KPI Dashboard

Sales Management & ISR Hired

Sales Teams Hired and Trained

Payer Reimbursement and Trade Discussions

Budget Impact Model and Health Economic Analysis and Publications

Investor Day 2018

LAUNCH

Planned

Complete

10/23/2018
Success Begins in the Hospital with Specialists
“Go-Home” Strategy to Minimize Hospital Stay

Launch and Beyond
- IDs
- ER HCPs
- Hospitalists
- Pulmonologists
- PharmD IDs
- Allied HCPs

Year 2 and Beyond
- Internal Medicine
- Primary Care Provider
- NPs, PAs
- Urgent Care
Paving The Path For a Successful Launch
Market Access Followed by Commercial Execution for Demand Generation

Oct ‘18 – Jan ‘19
Execution by Select Customer-Facing Team
✓ Contract negotiations
✓ Pre-orders
✓ Qualify key accounts
✓ Appointments

February ‘19 - Forward
Execution by Sales Force & Market Access Customer-Facing Teams
✓ Continue institutional access
✓ Demand generation
Field Force Has Two Simultaneous Objectives

Institutional Access + Demand Generation

Influencers:
- IDs
- PharmD IDs
- Pharmacy Directors
- Microbiologists

Trial & Usage
- Prescribers:
  - IDs
  - ER
  - Hospitalists
  - Pulmonologists

Adoption

Formulary/Protocols
Specialty Access & Buying

Institutional Access + Demand Generation = Adoption

NUZYRA™ (omadacycline)
Focused Launch Targeting Early Adopters
Expansion to ~80 Representatives by Year End 2019

- Launch in **February 2019** with **40 Sales Specialists**
- **Focusing on ‘Early Adopting’** HCPs in ‘high value’ institutions (~400), will drive institutional access
- **By end of 2019**, plan to have a total of **~80 Sales Specialists** targeting 800 institutions
- **Inside Sales Team will supplement** efforts of Sales Specialists and broaden outreach

**Physician Segments**

- **Early Adopter**
  - Focused on broad spectrum and efficacy
  - Convenient features with IV to oral transition

- **Late Adopter**
  - Wait for Early Adopters to trial and use
  - Guideline and protocol driven
NUZYRA Attributes Provide A Modern-Day Solution
Unmet Need Confirmed Through Physician Research

There are Unmet Needs that NUZYRA Will Address

- Lower C.diff Potential
- New Therapies to Overcome Drug Resistance
- Alternative to Quinolones
- Reduce Hospital Length of Stay
- Reduce Nursing Time
- More Oral Options
- Equivalent IV & Oral
- Reduce Usage of Multi-Drug Combinations
- Established Efficacy in a Monotherapy
- Known Safety Profile
- Modernized Tetracycline
- Confidence to Discharge Patient
- Once Daily Dosing

Physicians Recognize the Positive Attributes of NUZYRA

Source: Paratek Sponsored Market Research
NUZYRA: As First-line Therapy
Targeted Patient Profiles

CABP

- Alternative to fluoroquinolone + β-lactam allergic
- Prior C. difficile infection

ABSSSI

- Suspected polymicrobial infection + β-lactam / sulfa allergic
- Renal insufficiency + SSRI
Ensure Seamless Transition from Hospital to Home
Continuity of Care Providing Access to Oral NUZYRA

**Continuity of Care**
- Prevent gap in care
- Sample / Bridge Program (as needed)

**Distribution Network**
- IV Formulation
  - National & Regional Distributors
- Oral Formulation
  - National & Regional Pharmacies
  - Program allows for oral formulation pick-up at retail locations or home delivery

**Reimbursement Support Services**

**Affordability Program**

**HUB Services**
- Enables effective discharge process
Early Indicators to Track Performance

**Covered Lives**
- 3 months Post-Launch
  - 33% of covered lives under contract
- 12 months Post-Launch
  - 66% of covered lives under contract

**Institutional Access**
- 12 months Post-Launch
  - 70% of 800 targeted institutions
History Can Repeat Itself…

Today: Slower starts…But with the Right Attributes, a Strong Finish

Recent AB Launches: antibiotics launched since 2010 that have at least 36 months of data - Avycaz, Dalvance, Orbiact, Sivextro, Teflaro, & Zerbaxa
(does not include Dificid or new formulations/line extensions)

*MAT = 12-month rolling total

Source: NSP Data
NUZYRA Coming Soon…February 2019